Cargando…
Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella
Nontyphoidal Salmonellae cause a devastating burden of invasive disease in sub-Saharan Africa with high levels of antimicrobial resistance. Vaccination has potential for a major global health impact, but no licensed vaccine is available. The lack of commercial incentive makes simple, affordable tech...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6187145/ https://www.ncbi.nlm.nih.gov/pubmed/30262653 http://dx.doi.org/10.1073/pnas.1807655115 |
_version_ | 1783362972106620928 |
---|---|
author | Micoli, Francesca Rondini, Simona Alfini, Renzo Lanzilao, Luisa Necchi, Francesca Negrea, Aurel Rossi, Omar Brandt, Cornelia Clare, Simon Mastroeni, Pietro Rappuoli, Rino Saul, Allan MacLennan, Calman A. |
author_facet | Micoli, Francesca Rondini, Simona Alfini, Renzo Lanzilao, Luisa Necchi, Francesca Negrea, Aurel Rossi, Omar Brandt, Cornelia Clare, Simon Mastroeni, Pietro Rappuoli, Rino Saul, Allan MacLennan, Calman A. |
author_sort | Micoli, Francesca |
collection | PubMed |
description | Nontyphoidal Salmonellae cause a devastating burden of invasive disease in sub-Saharan Africa with high levels of antimicrobial resistance. Vaccination has potential for a major global health impact, but no licensed vaccine is available. The lack of commercial incentive makes simple, affordable technologies the preferred route for vaccine development. Here we compare equivalent Generalized Modules for Membrane Antigens (GMMA) outer membrane vesicles and O-antigen-CRM(197) glycoconjugates to deliver lipopolysaccharide O-antigen in bivalent Salmonella Typhimurium and Enteritidis vaccines. Salmonella strains were chosen and tolR deleted to induce GMMA production. O-antigens were extracted from wild-type bacteria and conjugated to CRM(197). Purified GMMA and glycoconjugates were characterized and tested in mice for immunogenicity and ability to reduce Salmonella infection. GMMA and glycoconjugate O-antigen had similar structural characteristics, O-acetylation, and glucosylation levels. Immunization with GMMA induced higher anti–O-antigen IgG than glycoconjugate administered without Alhydrogel adjuvant. With Alhydrogel, antibody levels were similar. GMMA induced a diverse antibody isotype profile with greater serum bactericidal activity than glycoconjugate, which induced almost exclusively IgG1. Immunization reduced bacterial colonization of mice subsequently infected with Salmonella. S. Typhimurium numbers were lower in tissues of mice vaccinated with GMMA compared with glycoconjugate. S. Enteritidis burden in the tissues was similar in mice immunized with either vaccine. With favorable immunogenicity, low cost, and ability to induce functional antibodies and reduce bacterial burden, GMMA offer a promising strategy for the development of a nontyphoidal Salmonella vaccine compared with established glycoconjugates. GMMA technology is potentially attractive for development of vaccines against other bacteria of global health significance. |
format | Online Article Text |
id | pubmed-6187145 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | National Academy of Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-61871452018-10-15 Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella Micoli, Francesca Rondini, Simona Alfini, Renzo Lanzilao, Luisa Necchi, Francesca Negrea, Aurel Rossi, Omar Brandt, Cornelia Clare, Simon Mastroeni, Pietro Rappuoli, Rino Saul, Allan MacLennan, Calman A. Proc Natl Acad Sci U S A Biological Sciences Nontyphoidal Salmonellae cause a devastating burden of invasive disease in sub-Saharan Africa with high levels of antimicrobial resistance. Vaccination has potential for a major global health impact, but no licensed vaccine is available. The lack of commercial incentive makes simple, affordable technologies the preferred route for vaccine development. Here we compare equivalent Generalized Modules for Membrane Antigens (GMMA) outer membrane vesicles and O-antigen-CRM(197) glycoconjugates to deliver lipopolysaccharide O-antigen in bivalent Salmonella Typhimurium and Enteritidis vaccines. Salmonella strains were chosen and tolR deleted to induce GMMA production. O-antigens were extracted from wild-type bacteria and conjugated to CRM(197). Purified GMMA and glycoconjugates were characterized and tested in mice for immunogenicity and ability to reduce Salmonella infection. GMMA and glycoconjugate O-antigen had similar structural characteristics, O-acetylation, and glucosylation levels. Immunization with GMMA induced higher anti–O-antigen IgG than glycoconjugate administered without Alhydrogel adjuvant. With Alhydrogel, antibody levels were similar. GMMA induced a diverse antibody isotype profile with greater serum bactericidal activity than glycoconjugate, which induced almost exclusively IgG1. Immunization reduced bacterial colonization of mice subsequently infected with Salmonella. S. Typhimurium numbers were lower in tissues of mice vaccinated with GMMA compared with glycoconjugate. S. Enteritidis burden in the tissues was similar in mice immunized with either vaccine. With favorable immunogenicity, low cost, and ability to induce functional antibodies and reduce bacterial burden, GMMA offer a promising strategy for the development of a nontyphoidal Salmonella vaccine compared with established glycoconjugates. GMMA technology is potentially attractive for development of vaccines against other bacteria of global health significance. National Academy of Sciences 2018-10-09 2018-09-27 /pmc/articles/PMC6187145/ /pubmed/30262653 http://dx.doi.org/10.1073/pnas.1807655115 Text en Copyright © 2018 the Author(s). Published by PNAS. https://creativecommons.org/licenses/by-nc-nd/4.0/ This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Biological Sciences Micoli, Francesca Rondini, Simona Alfini, Renzo Lanzilao, Luisa Necchi, Francesca Negrea, Aurel Rossi, Omar Brandt, Cornelia Clare, Simon Mastroeni, Pietro Rappuoli, Rino Saul, Allan MacLennan, Calman A. Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella |
title | Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella |
title_full | Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella |
title_fullStr | Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella |
title_full_unstemmed | Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella |
title_short | Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella |
title_sort | comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal salmonella |
topic | Biological Sciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6187145/ https://www.ncbi.nlm.nih.gov/pubmed/30262653 http://dx.doi.org/10.1073/pnas.1807655115 |
work_keys_str_mv | AT micolifrancesca comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella AT rondinisimona comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella AT alfinirenzo comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella AT lanzilaoluisa comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella AT necchifrancesca comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella AT negreaaurel comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella AT rossiomar comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella AT brandtcornelia comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella AT claresimon comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella AT mastroenipietro comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella AT rappuolirino comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella AT saulallan comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella AT maclennancalmana comparativeimmunogenicityandefficacyofequivalentoutermembranevesicleandglycoconjugatevaccinesagainstnontyphoidalsalmonella |